Wellchem

Haematology

Nuwiq

Nuwiq® is indicated for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). It is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII)] used to treat Hemophilia A. NUWIQ is not indicated for the treatment of von Willebrand Disease.

Fast and Accurate Control

Nuwiq® contains human coagulation factor VIII with no animal or human derived materials added during the manufacturing process or to the final medicinal product. It is a convenient twice-weekly dosing to effectively prevent bleeds in patients on personalised prophylaxis.

References

Key Features & Benefits

  • The First and Only Recombinant FVIII Produced in Human Cells Without Chemical Modification or Protein Fusion
  • Produced in human cells, not hamster cells
  • B-domain deleted, no chemical modification or protein fusion
  • High binding affinity to VWF (99% bound)
  • Minimizing unbound FVIII may reduce risk of inhibitor development
  • All Patients Experienced Fewer Bleeds with Nuwiq® Prophylaxis vs On-Demand Treatment with Another FVIII Product
Nuwiq

Related Brands